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Abstract: Nighttime fasting has been inconclusively associated with a reduced risk of cancer. The
purpose of this study was to investigate this association in relation to prostate cancer risk. We ex-
amined data from 607 prostate cancer cases and 848 population controls who had never worked in
night shift work from the Spanish multicase-control (MCC) study, 2008–2013. Through an interview,
we collected circadian information on meal timing at mid-age. We estimated odds ratios (OR) and
95% confidence intervals (CI) with unconditional logistic regression. After controlling for time of
breakfast, fasting for more than 11 h overnight (the median duration among controls) was associated
with a reduced risk of prostate cancer compared to those fasting for 11 h or less (OR = 0.77, 95%
0.54–1.07). Combining a long nighttime fasting and an early breakfast was associated with a lower
risk of prostate cancer compared to a short nighttime fasting and a late breakfast (OR = 0.54, 95% CI
0.27–1.04). This study suggests that a prolonged nighttime fasting duration and an early breakfast
may be associated with a lower risk of prostate cancer. Findings should be interpreted cautiously
and add to growing evidence on the importance of chrononutrition in relation to cancer risk.
Keywords: prostate cancer; prolonged nighttime fasting; early time-restricted feeding; circadian
rhythms; breakfast; chrononutrition
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1. Introduction
Prostate cancer is the most frequently diagnosed cancer in men and ranks as the third
cause of cancer mortality in Spain [1]. Several non-modifiable risk factors for prostate cancer
have been identified, including age, ethnicity and a family history of prostate cancer [2]. In
2019, following a first evaluation in 2007 of shift work that involves circadian disruption, the
International Agency for Research on Cancer (IARC) classified night shift work as probably
carcinogenic to humans, supported by limited evidence in humans for prostate, breast and
colon cancer [3,4]. Circadian rhythms allow the adaptation to daily environmental changes
and regulate multiple physiological activities in the organism following cycles of 24 h [5].
In the IARC report, several mechanistic hypotheses were proposed to explain the evaluated
association, including chronic inflammation, hormonal alterations, cell proliferation and
immunosuppression [3]. In the general population, circadian disruption as a result of
exposure to artificial light-at-night (ALAN) [6,7], sleep duration [8–10] and mutations in
clock genes [11], has also been associated with prostate cancer.
Although the light captured by the retina is the main synchronizer of the central
circadian system, the feeding–fasting cycle also plays a major role in the regulation of
peripheral clocks. Late-night eating has been associated with an increased prostate cancer
risk in a study in France [12]. Similarly, previous results from the multicase-control (MCC)
study in Spain found that having a long-time interval between supper and sleep was
associated with a statistically significant reduced risk of prostate cancer [13]. This protective
association was more pronounced in individuals with a morning chronotype, a human
attribute believed to have a genetic basis that reflects a personal preference for timing
of activity [13]. The morning chronotype was defined as having a mid-sleep time before
3:35 AM, based on the distribution among controls [13]. Results from the same study
showed that having an early supper was associated with a reduced risk of prostate cancer,
but results were not statistically significant [13]. Another study in adults reported an
association between nighttime snacking and increased body fatness [14], the latter classified
as a probable risk factor for prostate cancer [15,16].
Various fasting regimens have been associated with weight loss and have been recently
popularized [17]. Intermittent fasting is a form of fasting that consists of restricting the feeding
window to 8 h, therefore prolonging the nighttime fasting duration [17]. Prolonged nighttime
fasting has also been associated with a reduction in waist circumference, blood glucose
(HbA1c) levels and systemic inflammation, which may influence cancer risk [18,19]. Results
from the prospective Women’s Healthy Eating and Living study suggested that fasting for
13 h or more reduced the risk of breast cancer recurrence compared to a shorter fasting
period [20]. However, data from the NutriNet-Santé prospective cohort study showed that
duration of fasting overnight was not significantly associated with the risk of developing
prostate cancer [12]. Although nighttime fasting has been associated with a lower risk of
cancer outcomes, skipping breakfast has been linked with an increased risk of low-grade
inflammation [21].
Food behaviors, including time of supper and interval between supper and sleep, were
previously examined in the MCC study [13]. However, the associations with nighttime
fasting duration and time of breakfast were not evaluated. Given the current surge in
fasting as a new food behavior, in this study we investigate whether prolonged nighttime
fasting is associated with a reduced prostate cancer risk Additionally, we consider whether




The MCC study (http://www.mccspain.org, accessed on 6 April 2021) is a multicase-
control study conducted in 12 provinces of Spain between 2008 and 2013 [22]. Included in
this analysis were individuals between the ages of 20 and 85 with histological confirmation
of prostate cancer. As soon as possible after diagnosis, cancer cases were frequency matched
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based on age, sex and area with population controls. In each of the recruitment areas,
administrative records from primary healthcare centers were reviewed to randomly select
controls residing there for a minimum period of 6 months. For this study, participants who
did not respond to the follow-up circadian interview (N = 522) were excluded (Figure 1).
To avoid confounding, subjects ever doing night shift work were excluded (N = 535), with
night shift work defined as working partly or entirely between midnight and 6 AM for
3 nights or more per month [13]. Participants with missing data on nighttime fasting
(N = 93) were also excluded. In this analysis, 607 prostate cancer cases and 848 population
controls from 7 different regions (Madrid, Barcelona, Asturias, Huelva, Cantabria, Valencia
and Granada) were selected. Each of the Ethics committees of the included centers reviewed
and approved the study protocol. All subjects signed a written informed consent.
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2.2. Data Collection
A questionnaire was answered by participants in a face-to-face interview with a
trained interviewe [22]. We requ sted information o ge, sociodemographic fac ors,
family his o y of p ostate cancer, smoking, sleep duration, sl ep pr ble s and height and
weight one year bef re the interview, from which the body mass index (BMI) was calculate
as kg/m2. Exposure to indoor ALAN was assessed in the question aire through a Likert
scale ranging from total darkness, almost d rk and dim light to quite illuminated [6].
Outdoor ALAN exposure was also assessed but only for the cities of Barcelona and Madri ,
where satellite images were available [6]. Light exposure was modeled and attributed to
participants’ geocoded residences through Geographic Information System [6].
Following the interview, information on daily energy intake was gathered through a
semi-quantitative food frequency questionnaire answered at home and estimated using
the Centro de Enseñanza Superior de Nutrición y Dietética (CESNID) food composition ta-
ble [23]. Ten percent of the participants did not respond to the food frequency questionnaire.
A World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR)
score was constructed [24]. The WCRF/AICR score ranged from 0 to 6 and included in-
formation on body fatness, physical activity, foods and drinks that promote weight gain,
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plant foods, animal foods and alcoholic drinks. This variable was further categorized into
sex-specific tertiles based on the distribution in the control group [24].
Circadian data, including information on meal frequencies, duration and timings,
were assessed through a telephone interview conducted 6 months to 5 years after the initial
interview (median time 3 years) [13]. In this paper, we refer to these variables as dietary
circadian variables. Participants reported their dietary circadian variables on weekdays and
weekends at 40 years of age and during the year prior to the initial interview. Participants
younger than 40 years of age were only asked for the information on the year prior to
recruitment. Participants were also asked questions on sleep and timing of physical activity
and answered the Munich Chronotype Questionnaire [13]. Chronotype was estimated as
the standard mid-sleep time on free days, Mid-sleep time on free days (MSF) = [sleep onset
on a free day + (sleep duration on free day/2)], and mid-sleep time on free days corrected
for oversleeping on free days (MSFcorr) = MSF − [sleep duration on a free day − (sleep
duration on a working day/2)]. Further details have been described elsewhere [13].
2.3. Exposure and Outcome Assessment
Nighttime fasting duration was defined as the period elapsed between the last eating
episode before going to sleep and the first episode the following day. In the previous paper
from MCC, we investigated time of supper [13], but now time of last intake also considered
after supper snacks. For participants reporting not having breakfast, lunch was considered
as breakfast, understood as the wider concept of breaking the nightly fast. The cut-off point
for nighttime fasting distribution was set at 11 h (the median distribution among controls),
defining a categorical variable with two levels: 11 h or less of fast, the reference category,
versus more than 11 h of fast. We based the main analysis on patterns of weekdays and at
40 years of age, because weekdays are more representative of daily lifestyle habits, and this
also helped avoid having missing data on weekend patterns. We used data at 40 years of
age to avoid potential reverse causation since it has been reported that cancer can cause
anorexia (loss of appetite), thus affecting eating patterns [25].
Clinical information on prostate cancer aggressiveness determined by the Gleason
score was recorded from medical records. We did not use the new Gleason grading system
because of small numbers in some groups [26]. We classified cases into two groups: low-
grade aggressive prostate cancer (Gleason score = 6 or 3 + 4) and high-grade aggressive
prostate cancer (Gleason score 4 + 3 or higher), as it has been previously reported in the
literature [27].
2.4. Statistical Analyses
We compared the distribution of characteristics in prostate cancer cases and controls
and also prostate cancer risk factors according to nighttime fasting duration in controls. To
evaluate significant differences, chi-square tests and t-tests were applied to calculate the
p-value in categorical and continuous variables, respectively.
We assessed the correlation between nighttime fasting and the other dietary circadian
variables (time of supper, interval between supper and sleep and time of breakfast) using
Spearman’s correlation coefficient. We examined the linearity of the association between
nighttime fasting duration (continuous variable, in hours) and prostate cancer using
generalized additive models (GAM). We applied ANOVA, including the smoothing terms
versus the linear term model, to test this association’s linearity.
Odds ratios (OR) and 95% confidence intervals (CI) were estimated with unconditional
logistic regression using categorical exposure data. The crude model was adjusted for
age (continuous, years), center (Madrid, Barcelona, Asturias, Huelva, Cantabria, Valencia,
Granada) and for educational level (less than primary school, primary school, secondary
school, university). We included educational level in the crude model because population
controls had a higher level of education compared to cases [22]. Moreover, in our study
population, education was significantly associated both with the exposure and the outcome
(see Tables 1 and 2).
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Table 1. Basic characteristics of study population.
Controls (N = 848) Cases (N = 607) p-Value
Mean (SD) or N (%) Mean (SD) or N (%)
Age 66.0 (8.4) 65.6 (7.0) 0.372
BMI 27.5 (3.6) 27.5 (3.6) 0.967
Normal weight (<25 kg/m2) 225 (26.5) 153 (25.2)
0.850Overweight (≥25 to <30 kg/m2) 439 (51.8) 320 (52.7)
Obese (≥30 kg/m2) 184 (21.7) 134 (22.1)
Educational level
Less than primary school 115 (13.6) 104 (17.1)
<0.001
Primary school 247 (29.1) 244 (40.2)
Secondary school 264 (31.1) 142 (23.4)
University 222 (26.2) 117 (19.3)
Family history of prostate cancer
No 793 (93.5) 506 (83.4)
<0.001
Yes 55 (6.5) 101 (16.6)
Smoking
Never 242 (28.5) 171 (28.2)
0.571Ex-smoker 434 (51.2) 325 (53.5)
Current smoker 172 (20.3) 111 (18.3)
Chronotype
Morning 419 (50.5) 306 (50.5)
0.974Intermediate 303 (36.6) 224 (37.0)
Evening 107 (12.9) 76 (12.5)
Unknown 19 1
WCRF/AICR score
Low adherence a 307 (40.1) 203 (37.3)
0.004Medium adherence b 262 (34.2) 232 (42.6)
High adherence c 196 (25.6) 109 (20.0)
Unknown 83 63
Diabetes
No 671 (79.3) 518 (85.6)
0.003
Yes 175 (20.7) 87 (14.4)
Unknown 2 2
Indoor ALAN exposure
Total darkness 147 (17.4) 87 (14.4)
0.001
Almost dark 348 (41.2) 211 (34.9)
Dim light 261 (30.9) 204 (33.7)
Quite illuminated 88 (10.4) 103 (17.0)
Unknown 4 2
Nutrients 2021, 13, 2662 6 of 15
Table 1. Cont.
Controls (N = 848) Cases (N = 607) p-Value
Breakfast
No 17 (2.0) 3 (0.5)
0.001
Only weekends 3 (0.4) 12 (2.0)
Only weekdays 15 (1.8) 16 (2.6)
Always 809 (95.9) 575 (94.9)
Unknown 4 1
Time of breakfast
8:30 AM or before 466 (55.0) 314 (51.7)
0.227
After 8:30 AM or skip breakfast 382 (45.0) 293 (48.3)
Time of last intake
10 PM or later 294 (34.7) 227 (37.4)
0.3509:00 to <10 PM 439 (51.8) 311 (51.2)
Before 9 PM 115 (13.6) 69 (11.4)
Supper/sleep interval
1 h or less 186 (22.2) 169 (28.1)
0.034From >1 to ≤2 h 327 (39.0) 223 (37.0)
More than 2 h 326 (38.9) 210 (34.9)
Unknown 9 5
ALAN = artificial light at night; BMI = body mass index; N = sample size; NA = not applicable; SD = standard deviation; WCRF/AICR = World
Cancer Research Fund / American Institute for Cancer Research. a Men (0.25–3); Women (0.5–3.5). b Men (3.25–4); Women (3.75–4.25). c Men
(4.25–6); Women (4.5–6).
Table 2. Distribution of prostate cancer risk factors according to nighttime fasting duration in controls.
≤11 h of Fast
(N = 474)
>11 h of Fast
(N = 374) p-Value
Mean (SD) or N (%) Mean (SD) or N (%)
Age 65.5 (8.5) 66.5 (8.2) 0.070
BMI 27.4 (3.5) 27.6 (3.8) 0.384
Normal weight (<25 kg/m2) 121 (25.5) 104 (27.8)
0.198Overweight (≥25 to <30 kg/m2) 258 (54.4) 181 (48.4)
Obese (≥30 kg/m2) 95 (20.0) 89 (23.8)
Educational level
Less than primary school 50 (10.5) 65 (17.4)
<0.001
Primary school 115 (24.3) 132 (35.3)
Secondary school 161 (34.0) 103 (27.5)
University 148 (31.2) 74 (19.8)
Family history of prostate cancer
No 445 (93.9) 348 (93.0)
0.727
Yes 29 (6.1) 26 (7.0)
Smoking
Never 140 (29.5) 102 (27.3)
0.191Ex-smoker 230 (48.5) 204 (54.5)
Current smoker 104 (21.9) 68 (18.2)
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Table 2. Cont.
≤11 h of Fast
(N = 474)
>11 h of Fast
(N = 374) p-Value
Chronotype
Morning 219 (47.1) 200 (54.9)
0.080Intermediate 181 (38.9) 122 (33.5)
Evening 65 (14.0) 42 (11.5)
Unknown 9 10
WCRF/AICR score
Low adherence a 164 (38.2) 143 (42.6)
0.432Medium adherence b 154 (35.9) 108 (32.1)
High adherence c 111 (25.9) 85 (25.3)
Unknown 45 38
Diabetes
No 387 (81.8) 284 (76.1)
0.052
Yes 86 (18.2) 89 (23.9)
Unknown 1 1
Indoor ALAN exposure
Total darkness 63 (13.3) 84 (22.6)
0.005
Almost dark 203 (43.0 145 (39.0)
Dim light 151 (32.0) 110 (29.6)
Quite illuminated 55 (11.7) 33 (8.9)
Unknown 2 2
Breakfast
No 1 (0.2) 16 (4.3)
<0.001
Only weekends NA 3 (0.8)
Only weekdays 8 (1.7) 7 (1.9)
Always 465 (98.1) 344 (93.0)
Unknown NA 4
Time of breakfast
8:30 AM or before 417 (88.0) 49 (13.1)
<0.001
After 8:30 AM or skip breakfast 57 (12.0) 325 (86.9)
Time of last intake
10 PM or later 215 (45.4) 79 (21.1)
<0.0019:00 to <10 PM 233 (49.2) 206 (55.1)
Before 9 PM 26 (5.5) 89 (23.8)
Supper/sleep interval
1 h or less 110 (23.6) 76 (20.4)
0.553From >1 to ≤2 h 178 (38.1) 149 (40.1)
More than 2 h 179 (38.3) 147 (39.5)
Unknown 7 2
ALAN = artificial light at night; BMI = body mass index; N = sample size; SD = standard deviation; WCRF/AICR = World Cancer Research
Fund / American Institute for Cancer Research. a Men (0.25–3); Women (0.5–3.5). b Men (3.25–4); Women (3.75–4.25). c Men (4.25–6);
Women (4.5–6).
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Since there is limited prior evidence of determinants for both the exposure and the
outcome, we followed a mixed criterion for the selection of further potential confounders.
First, on the basis of the limited prior knowledge, we built a directed acyclic graph using
Daggity (Figure S1) [28]. The variables considered were family history of prostate cancer
(yes, no), adherence to a healthy lifestyle through the WCRF/AICR score (high, medium,
low), indoor ALAN (total darkness, almost dark, dim light, quite illuminated), outdoor
ALAN (continuous, cd/m2), sleep problems (yes, no) and duration (7 h or less, more
than 7 h), number of daily eating episodes (three or less, more than three), time of the
last intake (before 9 PM, 9:00 to <10 PM, 10 PM, or later) and the interval between the
time of supper and sleep (1 h or less, from >1 to 2 h, more than 2 h). “Time of breakfast”
was categorized in two levels (8:30 AM or before, after 8:30 or skip breakfast). Skipping
breakfast has been associated with negative metabolic outcomes, but in our study only
3 cases reported never having breakfast. We also considered timing of physical activity
(inactive, 8 AM–10 AM, 10 AM–12 PM, 12 PM–7 PM, 7 PM–11 PM, any other pattern), since
it has been recently reported that morning exercise may be associated with a lower risk of
prostate cancer compared to exercising later in the day [29]. Additionally, we considered
diabetes (yes, no) because its treatment can include changes in dietary habits and it has
been inconsistently suggested as a protective factor for prostate cancer [30–32]. Finally,
we included BMI (continuous, kg/m2), smoking (never, ex-smoker, current smoker) and
chronotype (morning, intermediate, evening).
In the adjusted model we included variables strongly associated with both the expo-
sure and outcome in our study population (see Tables 1 and 2) and variables changing the
association between nighttime fasting and prostate cancer risk by more than 10% (Table S1).
These variables were diabetes and indoor ALAN for the first criterion and breakfast time
as the second criterion. Less than 1% of data was missing in the selected covariates. Mul-
ticollinearity was assessed in the adjusted model through the variance inflation factor to
control for redundancy.
We explored whether there was evidence of effect modification of the association of
interest by chronotype, healthy lifestyle (assessed with the WCRF/AICR score) and time
of breakfast, including an interaction term in each of the models and examining results
from a likelihood ratio test. We also investigated the combined association of nighttime
fasting duration and time of breakfast with prostate cancer risk. The association between
nighttime fasting and prostate cancer aggressiveness was examined with a multinomial
logistic regression model. The statistical package R-4.0.0 (The R Project for Statistical
Computing, Vienna, Austria) was used for these analyses.
2.5. Sensitivity Analyses
We explored the role of nighttime fasting on days off and working days by com-
bining nighttime fasting data from weekdays and weekends (at 40 years of age). We
used a weighted mean giving a weight of 5/7 to weekdays and of 2/7 to weekends. We
also explored eliminating point outliers of the exposure distribution to exclude the most
extreme patterns. We considered as potential point outliers any observation below the
Q1 − (1.5*IQR) and above Q3 + (1.5*IQR). Nine (0.6%) and 35 observations (2.4%) were
identified and excluded, respectively. To test the robustness of our results, exposure the
previous year to the circadian interview was also considered, despite the potential bias due
to reverse causation. This model was adjusted for time of breakfast corresponding to the
year before the circadian interview and we assumed that exposure to indoor ALAN did
not change during these years.
The time elapsed between the inclusion in the study and the exposure assessment
from the circadian interview was long for some participants. Therefore, we did a sensitivity
analysis including only those participants that answered the interview 3 years or less after
the baseline questionnaire.
Nutrients 2021, 13, 2662 9 of 15
3. Results
3.1. Study Population
Characteristics of the included prostate cancer cases (N = 607) and matched con-
trols (N = 848) are shown in Table 1. Educational level (p-value < 0.001), family history of
prostate cancer (p-value < 0.001) and poor adherence to the WCRF/AICR recommendations
(p-value = 0.004) were significantly associated with prostate cancer. Having a shorter time
interval elapsed between supper and sleep (p-value = 0.034), not having breakfast consis-
tently (p-value = 0.001) and being exposed to indoor artificial light at night (p-value = 0.001)
were significantly associated with prostate cancer. Cases were less likely to have diabetes
(p-value = 0.003).
3.2. Nighttime Fasting and Prostate Cancer Risk
The median nighttime fasting duration in the control group was 11 h (interquartile
range 10–12). The distribution among controls of prostate cancer risk factors according to
categories of nighttime fasting duration is presented in Table 2. Highly educated subjects
tended to fast fewer hours overnight (p-value < 0.001). Participants with diabetes and
less exposed to indoor ALAN tended to have more extended nighttime fasting periods
(p-value = 0.052 and 0.005, respectively). Participants who never had breakfast or had the
first intake after 8:30 AM and the last intake before 9 PM tended to fast for more hours
(p-value < 0.001 for both variables).
A low positive correlation was observed between nighttime fasting duration and time
elapsed between supper and sleep (Figure S2A, with a Spearman’s correlation coefficient
of 0.12). Time of supper and nighttime fasting duration showed a low negative correlation
(Figure S2B, with a Spearman’s correlation coefficient of −0.36). High correlation was
found between nighttime fasting duration and time of breakfast (Figure S2C, Spearman’s
correlation coefficient of 0.83).
The GAM showed a slight reduction of prostate cancer risk with more extended
nighttime fasting (Figure S3A). When adjusting this model for time of breakfast, the
reduction in the prostate cancer risk associated with fasting was more evident (Figure S3B).
In the crude logistic regression model, fasting for more than 11 h overnight was associated
with a slightly non-significant reduced risk of prostate cancer compared to those fasting
for 11 h or less (OR = 0.92, 95% CI 0.73–1.16, Table 3). After adjusting for confounders, the
model showed that a more extended nightly fast was linked to a more potent reduction of
prostate cancer risk (adjusted model, OR = 0.77, 95% CI 0.54–1.07, Table 3). In this model,
having breakfast after 8:30 AM was associated with a non-significant increased risk of
prostate cancer (OR = 1.30, 95% CI 0.92–1.85) compared to having breakfast at 8:30 AM or
before. We did not find important collinearity in the adjusted model between the two diet
time-related variables.
Table 3. Association of nighttime fasting and prostate cancer risk.
Nighttime Fasting Controls N (%) Cases N (%) OR (95% CI) a OR (95% CI) b
≤11 h 474 (55.9) 342 (56.3) Ref Ref
>11 h 374 (44.1) 265 (43.7) 0.92 (0.73–1.16) 0.77 (0.54–1.07)
N = sample size; OR = odds ratio; 95% CI = 95% confidence interval. a Adjusted for age, center and education. b Adjusted for age, center,
education, diabetes (missing for 2 controls and 2 cases), indoor ALAN exposure (missing for 4 controls and 2 cases) and time of breakfast.
We also tried categorizing the exposure into three categories based on the distribution
of this variable in the control group: 10 h or less (reference category), more than 10 h
to 12 h, and more than 12 h (Table S2). In this analysis, fasting for more than 10 h to
12 h was associated with a slightly higher prostate cancer reduced risk than the most
extended fasting category. This difference was dissipated when adjusting for time of
breakfast, suggesting that this difference could be explained by the adverse effects of
postponing breakfast.
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3.3. Prostate Cancer Risk Stratified by Time of First Intake
The prostate cancer risk reduction with a prolonged nightly fast was moderately
stronger among those individuals having their breakfast at 8:30 or before (adjusted model,
OR = 0.60, 95% CI 0.33–1.04) compared to those having it later on the day or skipping it
(OR = 0.90, 95% CI 0.58–1.39, Table 4). Despite this pattern, confidence intervals overlapped
and the interaction in the adjusted model was not significant (p-value = 0.26, 1 degree
of freedom).
Table 4. Association of nighttime fasting and prostate cancer risk stratified by time of breakfast.
Nighttime Fasting Controls N (%) Cases N (%) OR (95% CI) a OR (95% CI) b
Breakfast at 8:30 AM or before
≤11 h 417 (89.5) 293 (93.3) Ref Ref
>11 h 49 (10.5) 21 (6.7) 0.66 (0.37–1.13) 0.60 (0.33–1.04)
Breakfast after 8:30 AM or skip breakfast
≤11 h 57 (14.9) 49 (16.7) Ref Ref
>11 h 325 (85.1) 245 (83.3) 0.87 (0.57–1.33) 0.90 (0.58–1.39)
N = sample size; OR = odds ratio; 95% CI = 95% confidence interval. a Adjusted for age, center and education. b Adjusted for age, center,
education, diabetes (missing for 2 controls and 2 cases), indoor ALAN exposure (missing for 4 controls and 2 cases) and chronotype
(missing for 19 controls and 1 case).
3.4. Association Combining Nighttime Fasting Duration and Time of Breakfast with Prostate
Cancer Risk
When combining both nighttime fasting duration and time of breakfast we observed
that the combination associated with a lower risk of prostate cancer was having a long
nighttime fasting and an early breakfast compared to a short nighttime fasting and a late
breakfast (OR = 0.54, 95% CI 0.27–1.04, Table 5). This association was maintained even after
adjusting for time of last intake and interval between supper and sleep.
Table 5. Association of nighttime fasting and time of breakfast with prostate cancer risk.
Controls N (%) Cases N (%) OR (95% CI) a OR (95% CI) b
Short nighttime fasting (≤11 h) and
late breakfast (>8:30 AM) 56 (6.6) 49 (8.1) Ref Ref
Short nighttime fasting (≤11 h) and
early breakfast (≤8:30 AM) 418 (49.3) 293 (48.3) 0.88 (0.57–1.36) 0.89 (0.57–1.39)
Long nighttime fasting (>11 h) and
late breakfast (>8:30 AM) 325 (38.3) 244 (40.2) 0.87 (0.57–1.33) 0.88 (0.57–1.36)
Long nighttime fasting (>11 h) and
early breakfast (≤8:30 AM) 49 (5.8) 21 (3.5) 0.58 (0.30–1.11) 0.54 (0.27–1.04)
N = sample size; OR = odds ratio; 95% CI = 95% confidence interval. a Adjusted for age, center and education. b Adjusted for age, center,
education, diabetes (missing for 2 controls and 2 cases) and indoor ALAN exposure (missing for 4 controls and 2 cases).
3.5. Prostate Cancer Risk Stratified by Chronotype
The association of prolonged fasting period overnight and reduced prostate cancer
risk was slightly more pronounced in morning chronotype individuals (adjusted model,
OR = 0.70, 95% CI 0.47–1.04) compared to intermediate and particularly evening ones
(OR= 0.80, 95% CI 0.50–1.27; OR = 0.99, 95% CI 0.51–1.92, Table 6). However, the likelihood
ratio test for interaction in the adjusted model showed a p-value = 0.60 with 2 degrees
of freedom. On the other hand, we observed no effect modification by adherence to the
WCRF/AICR score (Table S3).
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Table 6. Association of nighttime fasting and prostate cancer risk stratified by chronotype (missing for 19 controls and for 1 case).
Nighttime Fasting Controls N (%) Cases N (%) OR (95% CI) a OR (95% CI) b
Morning chronotype
≤11 h 219 (52.3) 170 (55.5) Ref Ref
>11 h 200 (47.7) 136 (44.5) 0.84 (0.61–1.15) 0.70 (0.47–1.04)
Intermediate chronotype
≤11 h 181 (59.7) 130 (58.0) Ref Ref
>11 h 122 (40.3) 94 (42.0) 0.97 (0.67–1.41) 0.80 (0.50–1.27)
Evening chronotype
≤11 h 65 (60.7) 41 (53.9) Ref Ref
>11 h 42 (39.3) 35 (46.1) 1.17 (0.63–2.18) 0.99 (0.51–1.92)
N = sample size; OR = odds ratio; 95% CI = 95% confidence interval. a Adjusted for age, center and education. b Adjusted for age, center,
education, diabetes (missing for 2 controls and 2 cases), indoor ALAN exposure (missing for 4 controls and 2 cases) and time of first intake.
3.6. Relative Risk among Cancer Subtypes
We evaluated the association between fasting overnight and aggressiveness of prostate
cancer (Gleason score) in a multinomial logistic regression model. The association of pro-
longed fasting overnight and reduced prostate cancer risk was similar in cases diagnosed
with a more aggressive prostate cancer subtype (Gleason score of 4 + 3 or higher) and
in those with a Gleason score of 6 or 3 + 4 (adjusted model, OR = 0.78, 95% CI 0.53–1.14
and OR = 0.71, 95% CI 0.42–1.19, Table 7). The differences among cancer subtypes were
non-significant (p-value = 0.97).
Table 7. Association of nighttime fasting and prostate cancer relative risk by cancer subtypes (missing for 17 cases).
Nighttime Fasting Controls N (%) Cases N (%) RRR (95% CI) a RRR (95% CI) b
Low aggressiveness
≤11 h 474 (55.9) 246 (56.7) Ref Ref
>11 h 374 (44.1) 188 (43.3) 0.91 (0.71–1.18) 0.78 (0.53–1.14)
High aggressiveness
≤11 h 474 (55.9) 86 (55.1) Ref Ref
>11 h 374 (44.1) 70 (44.9) 0.92 (0.63–1.33) 0.71 (0.42–1.19)
N = sample size; RRR = Relative risk ratio; 95% CI = 95% confidence interval. a Adjusted for age, center and education. b Adjusted for age,
center, education, diabetes (missing for 2 controls and 2 cases), indoor ALAN exposure (missing for 4 controls and 2 cases) and time of
first intake.
3.7. Sensitivity Analyses
Further adjustment of the model with other potential confounders did not change
the estimates (Table S1). Combining data from weekdays and weekends did not result in
different estimates than on weekdays only (data not shown). Removing the outliers of
the exposure variable distribution also had a minimal effect on estimates (adjusted model,
OR = 0.76, 95% CI 0.54–1.06, Table S4). The GAM in this reduced dataset showed the same
pattern (see Figure S3C,D).
The median nighttime fasting duration reported one year before the inclusion in the
study in the control group was 11.50 h (interquartile range 10.50–12.50). Models built with
data on nighttime fasting during weekdays reported one year before diagnosis or before
inclusion in the study for the controls changed the direction of the association (adjusted
model OR = 1.13, 95% CI 0.88–1.46, Table S5). Analyzing the cancer subtypes, we observed
that the relative risk ratio for aggressive prostate cancer cases (adjusted RRR = 1.23, 95% CI
0.82–1.84, Table S6) was slightly higher than for less aggressive cases (adjusted RRR = 1.10,
95% CI 0.83–1.46, Table S6).
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In a model that excluded participants answering the circadian interview more than
3 years later from the baseline interview strengthened the findings (participants interviewed
within 3 years: OR = 0.68, 95% CI 0.41–1.13; all participants: OR = 0.77, 95% CI 0.54–1.07).
4. Discussion
This is one of the first studies to examine the association between nighttime fasting
duration and cancer risk. These findings suggest a possible lower risk of prostate cancer
with longer overnight fasting time, especially when feeding is synchronized with the
appropriate circadian timing by having an early breakfast.
From an evolutionary perspective, the benefits of a prolonged period of fast overnight
are plausible. Life on earth has evolved to adapt and anticipate daily environmental oscilla-
tions resulting from the 24 h rotation of our planet. Natural selection drove the development
of circadian rhythms enabling the daily optimization of energy acquisition, including sun-
light (for photosynthetic organisms) or food [33]. The circadian clock permitted organisms
to be prepared and aroused to access food when available and store supplies and undergo
repairment processes during fasting hours, improving metabolic fitness and survival [33].
The extensive discussion on the benefits of nighttime fasting in mass media (e.g., Twitter)
that are frequently based on this evolutionary perspective is not, however, backed by
reliable population data.
Prolonged periods of fast overnight have been linked to a significant improvement
in glycemic control and inflammation biomarkers, potentially explaining a lower risk of
prostate cancer [18,19]. Our results are consistent with those of the prospective WHEL study,
showing that fasting for less than 13 h was associated with a 36% increased hazard of breast
cancer recurrence than a more extended fasting period [20]. Similarly to what we found,
the prospective study from the NutriNet-Santé cohort showed that each hour increase in
time of first intake was associated with a 17% increase in the hazard of developing PCa
(HR = 1.17, 95% CI 0.96–1.43) [12]. However, contrary to what we found, even adjusting
for this confounding effect of time of breakfast, nighttime fasting duration was associated
with a slight increase in the hazard of developing prostate cancer in this study population
(HR= 1.12, 95% CI 0.93–1.34) [12]. Differences between findings of epidemiological studies
might be explained because of varying methods, sample sizes and time intervals examined.
It has been previously reported that time of supper [12,13] and time elapsed between
supper and sleep [13] are associated with breast and prostate cancer. To disentangle these
effects from the effects of nighttime fasting, we inspected their correlation and we explored
adjustment of the crude model for these variables. We found low correlation between
nighttime fasting duration and time of supper and with time interval between supper and
sleep. Similarly, when we explored adjusting our basic model for time of last intake and
for time interval between supper and sleep, the estimates did not significantly change.
These results show that the potentially protective association between a prolonged nightly
fasting period and reduced prostate cancer risk might be complementary to the protective
association of having a larger time interval between supper and sleep.
Fasting regimens that promote long periods of fasting overnight, even by skipping
breakfast, have become increasingly popular. Our results suggest that the time of breakfast
is confounding the association between nighttime fasting and prostate cancer risk and that
elongating the nightly period of fast by skipping breakfast might be counterproductive.
Nighttime fasting is most beneficial when the eating window starts early in the morning,
a form of intermittent fasting known as early time-restricted feeding [34]. Time-of-day
variations in the benefits of nightly fasting can be explained by fluctuations of the circadian
rhythms, which can also vary across chronotypes. The optimal time for food intake might
be in the early hours of the day when diet-induced thermogenesis, glucose tolerance,
insulin sensitivity, pancreatic beta-cell responsiveness and oxidation of fatty acids are
higher [35].
Our study shows that in morning chronotype individuals, the association between
a prolonged period overnight and a prostate cancer risk reduction is slightly larger than
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other chronotypes. This association was independent of the time of the first intake. On
the contrary, in evening chronotype individuals, long nighttime fasting was not associated
with lower prostate cancer risk. This may be explained by a higher frequency of chronic
sleep deprivation and social jet-lag among late chronotypes, especially when working on
early morning work schedules [36].
Reverse causation might explain the differences observed between the analyses of
habits at 40 years of age and those shortly before disease or inclusion in the study. A
possible explanation may be that eating and sleep habits one year before diagnosis might
be reflecting a cancer-related loss of appetite or other early disease-related changes in
lifestyle [25].
The strengths of this research include the novelty of the research question, the large
sample size, the adjustment for a wide variety of well-measured confounders and the
validated questionnaires to assess diet and the individual chronotype. As limitations, one
of the primary concerns is that this assessment is subject to recall bias [13]. We tried
to minimize this bias by requesting data on the timing of diet at mid-life. Additionally,
in a sensitivity analysis, we explored excluding those participants with a longer time
elapsed between inclusion in the study and exposure assessment in the circadian interview
and, therefore, more prone to recall bias. After excluding these participants, estimates
for our association of interest were strengthened. Meal timings and diet quality were
assessed in one time point and these are behaviors prone to fluctuations. Future studies
should include multiple time assessments to increase the validity of the results. A further
inherent limitation of studies on prostate cancer is the lack of knowledge of this cancer’s
non-genetic risk factors that could result in uncontrolled confounding. Finally, circadian
patterns, including sleep timing and duration, light exposure and meal timings, are all
interconnected. To improve public health recommendations, a future approach could be to
analyze these behaviors in an integrated manner.
5. Conclusions
To conclude, this is one of the first studies with epidemiological data examining the
association between nighttime fasting duration and prostate cancer risk and to consider
the time window of this period of fasting. Complementing the previous results from
the MCC study that showed a beneficial association between an early supper and a long
supper–sleep time interval, our results suggest that lengthening the fasting period could
be associated with a lower risk of this cancer, especially when having an early breakfast.
This research highlights the importance of considering a circadian perspective, such as the
time window of nighttime fasting and combined effects of meal timing aspects, in studies
evaluating dietary and sleep determinants of cancer.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nu13082662/s1. Figure S1. Directed acyclic graph representing the potential association
between nighttime fasting duration and prostate cancer risk; Figure S2. Scatter plot for each of the
correlations among controls; Figure S3. Generalized additive model examining the linearity of the
association between nighttime fasting duration (continuous variable, in hours) and prostate cancer
risk; Table S1. Examination of further adjustment with potential confounders; Table S2. Association
of nighttime fasting duration with prostate cancer risk. Exposure variable categorized into three
levels based on the distribution of this variable in the control group; Table S3. Association of
nighttime fasting and prostate cancer risk stratified by adherence to the WCRF/AICR score; Table S4.
Association of nighttime fasting duration with prostate cancer risk excluding outliers; Table S5.
Association of nighttime fasting duration with prostate cancer risk based on information on dietary
habits the year before the circadian interview; Table S6. Prostate cancer relative risk by cancer
subtypes with information on dietary habits the year before the circadian interview.
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